Drug intelligence / Profile preview

FL776

Development stage: Preclinical
Lead developer: Canget BioTekpharma
Modality: Small Molecules
Administration: Intraperitoneal

Overview

FL776 is a small molecule antineoplastic agent being developed by Canget BioTekpharma as a back-up compound to their lead asset, FL118. It is specifically positioned for the treatment of colorectal cancer. Like FL118, FL776 is designed to target and inhibit the expression of multiple cancer-promoting genes, including the RNA helicase DDX5 (p68) and several anti-apoptotic proteins such as survivin, Mcl-1, XIAP, and cIAP2. Additionally, it has been reported to target mutant KRAS (mKras). By simultaneously suppressing these key survival and resistance factors, FL776 aims to overcome drug resistance and inhibit tumor growth in colorectal cancer models. It is currently in the preclinical stage of development.

Targets

DDX5 (Phosphorylated-p68 RNA helicase)UBE2T (Ubiquitin-conjugating enzyme E2 T)

Beyond the preview

Go deeper on FL776.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FL776.

Explore the full profile